In this episode of Discovery Matters, we discuss the exciting potential of lipid nanoparticles (LNPs) to deliver genetic material and therapeutics to target cells and tissues. We are joined by Lloyd Jeffs, Senior Director of Biopharma Services at Precision NanoSystems, and Prof Dan Peer, Director of the Laboratory of Precision Nanomedicine at Tel Aviv University. Dan shares how his team has developed siRNA LNPs to deliver treatment more efficiently for ovarian cancer patients. From Dan's unique perspective, learn why this technology is cutting-edge, and why it may help defeat one of mankind’s biggest enemies— cancer.

Transcript

Show notes

Therapeutic gene silencing of CKAP5 leads to lethality in genetically unstable cancer cells | Science Advances

Neuroscientists decoded a Pink Floyd song using people’s brain activity (sciencenews.org)

Nutrients | Free Full-Text | Does Pizza Consumption Favor an Improved Disease Activity in Rheumatoid Arthritis? (mdpi.com)

Keywords: ovarian cancer, nanoparticles, lipid nanoparticles, genomic medicine, tumour, nucleic acids, cells, chemotherapy, drug, mrna, patients, sirna, rna.